Unlock instant, AI-driven research and patent intelligence for your innovation.

A fusion protein, its pharmaceutical composition and use

A fusion protein and composition technology, applied in the field of fusion proteins, can solve problems such as difficulty in use and short half-life, and achieve the effects of promoting cartilage repair, long half-life, and promoting new bone formation

Active Publication Date: 2022-01-14
LINK HEALTH GRP +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the half-life of AC-100 is relatively short, and its plasma half-life is only about 20 minutes, so it is difficult to be used in the treatment of diseases (such as osteoporosis) that require systemic administration. Drug frequency, it is possible to meet the urgent clinical needs in the field of orthopedic disease treatment, and has broad application prospects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A fusion protein, its pharmaceutical composition and use
  • A fusion protein, its pharmaceutical composition and use
  • A fusion protein, its pharmaceutical composition and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Synthesis of Example 1 AC-100 Peptide

[0040] AC-100 peptide (SEQ ID NO: 1) was entrusted to Shanghai Aobo Biotechnology Co., Ltd. to synthesize by conventional solid-phase technology, and the purity of the synthesized peptide was >98%.

Embodiment 2

[0041] Construction and expression of embodiment 2 recombinant fusion protein strain

[0042] The construction of recombinant expression strains of fusion proteins HSA021-1 and HSA021-2 was entrusted to Nanjing GenScript Biotechnology Co., Ltd. The main steps are: synthesizing the target gene (SEQ ID NO: 2, corresponding to the nucleotide sequence encoding HSA021-1, which contains the sequence encoding the signal peptide; SEQ ID NO: 4, corresponding to the nucleotide sequence encoding HSA021-2 sequence, which contains the sequence encoding the signal peptide), was connected to the expression yeast expression vector pPICZaA through the same digestion by XhoI / NotI double digestion, and 10 μg of the expression vector after the connection was used to transfect Pichia pastoris (Pichia pastoris) X-33 , PCR identified positive clones. Selected positive clones were cultured in BMGY medium, OD 600 When it reached 3.0, the cells were harvested, resuspended in BMGY medium, and induced ...

Embodiment 3

[0044] Example 3 Effects on Bone Marrow Mesenchymal Stem Cells (BMSCs)

[0045] Three 8-week-old SD rats were killed by dislocation. After being sterilized with 70% ethanol, the abdominal cavity was cut open and the femur was separated. Use a syringe to draw low-sugar DMEM culture solution (containing 1 mL / L heparin) to flush the bone marrow cavity repeatedly to flush out the bone marrow.

[0046] The bone marrow fluid was made into a single-cell suspension, and DMEM-F12 complete medium containing 10% FBS (fetal bovine serum, fetal bovine serum) was added, and 10 7 The density of each / mL was inoculated in a culture flask, placed at 37°C, 5% CO 2 Cultivate in an incubator, change the culture medium after 48 hours, and then change the culture medium every 3 days to remove non-adherent hematopoietic cells. When the cells reach 80% to 90%, subculture, add the complete culture medium of mesenchymal stem cells to resuspend the cells, and store at 37°C, 5% CO 2 cultured in an incu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a fusion protein, its pharmaceutical composition and application, and belongs to the field of fusion proteins. The fusion protein of the present invention includes two molecules of AC-100 connected to human serum albumin through a linker, and the amino acid sequence of the AC-100 is shown in SEQ ID NO:1. The two molecules of AC-100 in the fusion protein of the present invention show a synergistic effect, have a significant effect of promoting cartilage repair and new bone formation, and can be used to repair cartilage, treat osteoarthritis, osteoporosis or fracture; at the same time, the fusion protein of the present invention The protein overcomes the instability and short half-life of AC-100 drugs, and has a significantly longer half-life in plasma and joint cavity, which is conducive to reducing the frequency and dosage of administration.

Description

technical field [0001] The invention relates to a fusion protein, its pharmaceutical composition and application, and belongs to the field of fusion proteins. Background technique [0002] Osteoarthritis (OA) is a common joint disease characterized by joint pain and stiffness. Cartilage damage is the main cause of osteoarthritis. The disease occurs frequently after middle age, and women are more than men. The prevalence rate of the 40-year-old crowd is 10% to 17%, that of the over 60-year-old is 50%, and that of the over-75-year-old crowd is as high as 80%. The disease has a certain rate of disability. With the aging population, osteoarthritis will become an important issue affecting people's quality of life, and the market demand for osteoarthritis drugs will continue to expand. [0003] At present, clinically, the therapeutic drugs for osteoarthritis are divided into specific therapeutic drugs and non-specific therapeutic drugs. Non-specific therapeutic drugs are mainl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00A61K38/18A61K47/62A61P19/02A61P19/00A61P19/10
Inventor 宋燕许元生张时群苏博雅
Owner LINK HEALTH GRP
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com